𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Proliferation inhibition of cisplatin and aquaporin 5 expression in human ovarian cancer cell CAOV3

✍ Scribed by Jianhua Yang; Chunxiao Yan; Wei Zheng; Xuejun Chen


Publisher
Springer
Year
2011
Tongue
English
Weight
489 KB
Volume
285
Category
Article
ISSN
0003-9128

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Akt promotes cisplatin resistance in hum
✍ Michael Fraser; Tao Bai; Benjamin K. Tsang 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 736 KB

## Abstract Resistance to cisplatin‐based chemotherapy is a major cause of treatment failure in human ovarian cancer. Wild‐type __TP53__ status is often, but not always, associated with cisplatin sensitivity, suggesting that additional factors may be involved. Overexpression/activation of the phosp

Mechanism of interaction between cisplat
✍ Alissar Nehmé; Nicolas Albin; Marie Josée Caliaro; Sylvie Guichard; Suzanne Joza 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 857 KB

## Abstract Human ovarian carcinoma cells (2008 and its cisplatin‐resistant sub‐line 2008/C13\*) were sensitized to cisplatin by treatment with human recombinant gamma interferon (IFNγ). IFNγ produced no significant change in the uptake of CDDP. Exposure of 2008 and 2008/C13\* cells to IFNγ resulte

Stimulation of lipocalin-type prostaglan
✍ Bing Su; Ming Guan; Jing Xia; Yuan Lu 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 118 KB

## Abstract Lipocalin‐type prostaglandin D synthase (LPGDS; PGH~2~D‐isomerase; EC 5.3.99.2) is a bifunctional protein first identified in the mammalian brain. It acts as a PGD~2~‐producing enzyme and a retinoid transporter. Recent studies have shown that LPGDS is anomalously expressed in ovarian tu

Inhibition of survivin reduces cell prol
✍ Zhihong Ai; Lianhua Yin; Xianrong Zhou; Ying Zhu; Dongmei Zhu; Yinhua Yu; Youji 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 765 KB

## Abstract ## BACKGROUND Endometrial cancer is a common gynecologic malignancy among women. The molecular mechanisms involved in the progression of endometrial cancer are unclear, which has hampered the development of an effective treatment. Survivin, a newly identified member of the inhibitor of